The company's primary focus is on developing its product candidate, Ensifentrine, which has the potential to be the first therapy for respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Ensifentrine has shown statistically significant and clinically meaningful improvements in lung function and reduced the rate of COPD exacerbations in clinical trials. Verona Pharma is led by a management team with a successful track record in respiratory therapies and is listed on the Nasdaq Global Market.